X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs GLENMARK PHARMA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER GLENMARK PHARMA PFIZER/
GLENMARK PHARMA
 
P/E (TTM) x 33.4 19.9 167.7% View Chart
P/BV x 5.0 3.6 139.5% View Chart
Dividend Yield % 0.8 0.3 224.5%  

Financials

 PFIZER   GLENMARK PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-17
GLENMARK PHARMA
Mar-17
PFIZER/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,055993 206.9%   
Low Rs1,651729 226.4%   
Sales per share (Unadj.) Rs429.8325.5 132.0%  
Earnings per share (Unadj.) Rs73.639.3 187.3%  
Cash flow per share (Unadj.) Rs87.448.7 179.5%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %1.10.2 464.7%  
Book value per share (Unadj.) Rs528.7159.2 332.1%  
Shares outstanding (eoy) m45.75282.17 16.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.32.6 163.0%   
Avg P/E ratio x25.221.9 114.9%  
P/CF ratio (eoy) x21.217.7 119.9%  
Price / Book Value ratio x3.55.4 64.8%  
Dividend payout %27.25.1 533.8%   
Avg Mkt Cap Rs m84,777242,991 34.9%   
No. of employees `0002.813.0 21.9%   
Total wages/salary Rs m3,03916,408 18.5%   
Avg. sales/employee Rs Th6,925.97,083.9 97.8%   
Avg. wages/employee Rs Th1,070.41,265.4 84.6%   
Avg. net profit/employee Rs Th1,186.3855.1 138.7%   
INCOME DATA
Net Sales Rs m19,66391,857 21.4%  
Other income Rs m1,012374 270.7%   
Total revenues Rs m20,67492,230 22.4%   
Gross profit Rs m3,49120,367 17.1%  
Depreciation Rs m6292,644 23.8%   
Interest Rs m102,373 0.4%   
Profit before tax Rs m3,86415,724 24.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,304-810 -161.1%   
Tax Rs m1,8013,827 47.1%   
Profit after tax Rs m3,36811,088 30.4%  
Gross profit margin %17.822.2 80.1%  
Effective tax rate %46.624.3 191.5%   
Net profit margin %17.112.1 141.9%  
BALANCE SHEET DATA
Current assets Rs m20,78968,746 30.2%   
Current liabilities Rs m7,87027,027 29.1%   
Net working cap to sales %65.745.4 144.7%  
Current ratio x2.62.5 103.9%  
Inventory Days Days6085 70.3%  
Debtors Days Days2296 23.5%  
Net fixed assets Rs m9,17524,132 38.0%   
Share capital Rs m458282 162.1%   
"Free" reserves Rs m23,73144,643 53.2%   
Net worth Rs m24,18944,925 53.8%   
Long term debt Rs m2545,363 0.1%   
Total assets Rs m32,706117,639 27.8%  
Interest coverage x403.57.6 5,291.4%   
Debt to equity ratio x01.0 0.1%  
Sales to assets ratio x0.60.8 77.0%   
Return on assets %10.311.4 90.2%  
Return on equity %13.924.7 56.4%  
Return on capital %21.419.1 111.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6356,152 0.1%   
Fx outflow Rs m4,0678,084 50.3%   
Net fx Rs m-4,00448,068 -8.3%   
CASH FLOW
From Operations Rs m3,2886,574 50.0%  
From Investments Rs m-2,496-7,124 35.0%  
From Financial Activity Rs m-8265,432 -15.2%  
Net Cashflow Rs m-351,992 -1.7%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 6.9 108.7%  
FIIs % 4.9 34.4 14.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 10.5 225.7%  
Shareholders   85,207 56,727 150.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Oil Prices; RBI Minutes and Top Stocks in Action Today(Pre-Open)

Indian share markets surged on Wednesday, snapping a two-day losing streak led by gains Reliance Industries and bank stocks.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Jun 20, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS